Characteristics and outcomes of patients with clinical t1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort.
Standard
Characteristics and outcomes of patients with clinical t1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. / Fritsche, Hans-Martin; Burger, Maximilian; Svatek, Robert S; Jeldres, Claudio; Karakiewicz, Pierre I; Novara, Giacomo; Skinner, Eila; Denzinger, Stefan; Fradet, Yves; Isbarn, Hendrik; Bastian, Patrick J; Volkmer, Bjoern G; Montorsi, Francesco; Kassouf, Wassim; Tilki, Derya; Otto, Wolfgang; Capitanio, Umberto; Izawa, Jonathan I; Ficarra, Vincenzo; Lerner, Seth; Sagalowsky, Arthur I; Schoenberg, Mark; Kamat, Ashish; Dinney, Colin P; Lotan, Yair; Shariat, Shahrokh F.
In: EUR UROL, Vol. 57, No. 2, 2, 2010, p. 300-309.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Characteristics and outcomes of patients with clinical t1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort.
AU - Fritsche, Hans-Martin
AU - Burger, Maximilian
AU - Svatek, Robert S
AU - Jeldres, Claudio
AU - Karakiewicz, Pierre I
AU - Novara, Giacomo
AU - Skinner, Eila
AU - Denzinger, Stefan
AU - Fradet, Yves
AU - Isbarn, Hendrik
AU - Bastian, Patrick J
AU - Volkmer, Bjoern G
AU - Montorsi, Francesco
AU - Kassouf, Wassim
AU - Tilki, Derya
AU - Otto, Wolfgang
AU - Capitanio, Umberto
AU - Izawa, Jonathan I
AU - Ficarra, Vincenzo
AU - Lerner, Seth
AU - Sagalowsky, Arthur I
AU - Schoenberg, Mark
AU - Kamat, Ashish
AU - Dinney, Colin P
AU - Lotan, Yair
AU - Shariat, Shahrokh F
PY - 2010
Y1 - 2010
N2 - BACKGROUND: Management of T1 grade 3 (T1G3) urothelial carcinoma of the bladder (UCB), with its variable behaviour, represents one of the most difficult challenges for urologists and patients alike. OBJECTIVE: To evaluate the characteristics and long-term outcome of patients with clinical T1G3 UCB treated with radical cystectomy (RC). DESIGN, SETTING, AND PARTICIPANTS: Data from 1136 patients treated with RC for clinical T1G3 UCB without neoadjuvant chemotherapy were collected at 12 centres located in Europe, the United States, and Canada. Median age was 67 yr (range: 29-94), with a male-to-female ratio of 4:1. MEASUREMENTS: Patients' characteristics and outcome are evaluated. RESULTS AND LIMITATIONS: Of the 1136 patients, 33.4% had non-organ-confined stage at cystectomy, and 16.2% had lymph node (LN) metastasis; 49.7% were upstaged after RC to muscle-invasive disease, while 21.4% were downstaged to lower than T1G3. Within a median follow-up of 48 mo, 35.5% of patients died of metastatic UCB. CONCLUSIONS: Approximately half of the patients treated with RC without neoadjuvant chemotherapy for clinical T1G3 UCB are upstaged to muscle-invasive UCB. These rates support the inadequacy of clinical decision making based on current treatment paradigms and staging tools. Therefore, identification of patients with clinical T1G3 disease at high risk of disease progression is of the utmost importance, as these patients are likely to benefit from early RC.
AB - BACKGROUND: Management of T1 grade 3 (T1G3) urothelial carcinoma of the bladder (UCB), with its variable behaviour, represents one of the most difficult challenges for urologists and patients alike. OBJECTIVE: To evaluate the characteristics and long-term outcome of patients with clinical T1G3 UCB treated with radical cystectomy (RC). DESIGN, SETTING, AND PARTICIPANTS: Data from 1136 patients treated with RC for clinical T1G3 UCB without neoadjuvant chemotherapy were collected at 12 centres located in Europe, the United States, and Canada. Median age was 67 yr (range: 29-94), with a male-to-female ratio of 4:1. MEASUREMENTS: Patients' characteristics and outcome are evaluated. RESULTS AND LIMITATIONS: Of the 1136 patients, 33.4% had non-organ-confined stage at cystectomy, and 16.2% had lymph node (LN) metastasis; 49.7% were upstaged after RC to muscle-invasive disease, while 21.4% were downstaged to lower than T1G3. Within a median follow-up of 48 mo, 35.5% of patients died of metastatic UCB. CONCLUSIONS: Approximately half of the patients treated with RC without neoadjuvant chemotherapy for clinical T1G3 UCB are upstaged to muscle-invasive UCB. These rates support the inadequacy of clinical decision making based on current treatment paradigms and staging tools. Therefore, identification of patients with clinical T1G3 disease at high risk of disease progression is of the utmost importance, as these patients are likely to benefit from early RC.
M3 - SCORING: Zeitschriftenaufsatz
VL - 57
SP - 300
EP - 309
JO - EUR UROL
JF - EUR UROL
SN - 0302-2838
IS - 2
M1 - 2
ER -
